UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,102	12/07/2004	Takayuki Abe	1141/73569	1040
23432 7590 10/16/2008 COOPER & DUNHAM, LLP 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036		8	EXAMINER	
			LEACH, CRYSTAL I	
NEW TORK, I	N1 10050	A		PAPER NUMBER
			3737	
			MAIL DATE	DELIVERY MODE
			10/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/517,102	ABE ET AL.			
		Examiner	Art Unit			
		CRYSTAL I. LEACH	3737			
	The MAILING DATE of this communication ap		1			
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
_	Responsive to communication(s) filed on <u>05</u>	April 2007				
2a)□	• • • • • • • • • • • • • • • • • • • •	is action is non-final.				
3)□	<b>/—</b>		osecution as to the merits is			
J)ا	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
	4)⊠ Claim(s) <u>1-9 and 11-13</u> is/are pending in the application.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
· · _ ·	· · · · · · · · · · · · · · · · · · ·					
· <u> </u>	S)⊠ Claim(s) <u>1-9 and 11-13</u> is/are rejected. 7)□ Claim(s) is/are objected to.					
' =	Claim(s) are subject to restriction and	or election requirement				
ا ا	are subject to restriction and	or election requirement.				
Applicati	on Papers					
9)□	The specification is objected to by the Examir	ner.				
10)🛛	10)⊠ The drawing(s) filed on <u>07 December 2004</u> is/are: a)  accepted or b)  objected to by the Examiner.					
	Applicant may not request that any objection to th	e drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2)  Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date 4/14/2008.	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal R 6) Other:	oate			

Application/Control Number: 10/517,102 Page 2

Art Unit: 3737

## Response to Arguments

1. Applicant's arguments with respect to claim1-9 and 11 have been considered but are most in view of the new ground(s) of rejection.

### **DETAILED ACTION**

#### Information Disclosure Statement

2. The Information Disclosure Statements (IDS) submitted on April 14, 2008 is in compliance with 37 CFR 1.97 and 1.98. The references therein have been considered.

# Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 1-4 and 6-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaufman et al. (6,690,961).

Kaufman et al. teach a magnetic resonance imaging apparatus (Abstract, line 1) comprising: an imaging means capable of applying high-frequency magnetic fields and gradient magnetic fields to an object to be placed in a static magnetic field in accordance with a pulse sequence of dynamic measurement for continuously obtaining a plurality of time-series images and for measuring NMR signals emitted from the object to be examined (col.1, lines 57-67; col. 4, lines 27-40), a signal processing means capable of forming images of a desired tissue of the object to be examined from the

Art Unit: 3737

NMR signals (col. 1, lines 64-67; col. 5, lines 55-57 and 61-67), a display means capable of displaying the images (col. 4, lines 62-64), and a control means capable of controlling the imaging means and the signal processing means (col. 4, lines 43-55; col. 5, lines 55-67); wherein the imaging means is provided with a monitoring mode in which a desired slab of the object to be examined is measured using a pulse sequence (col. 7. lines 17- col. 5, lines 4-43; col. 6, lines 43-46) for the dynamic measurement under a condition of applying gradient magnetic fields with a low spatial resolution and a substantial measurement mode in which the same slab is measured using the same pulse sequence under a condition of applying gradient magnetic fields with a high spatial resolution, and the control means has a mode switching means capable of switching from the monitoring mode to the substantial measurement mode and the switching means switches the monitoring mode to the substantial measurement mode with desired timing during the monitoring mode is performed (col. 5, line 35 – col. 7, line 29; col. 7, lines 57-58). See figure 1. Kaufman et al. teach that the apparatus is capable of extracting reference data from the dynamic measurement data acquired in the monitoring mode, and a temporal change of the extracted reference data is displayed on said displaying means (col. 7, lines 17-23 and lines 30-46). Kaufman et al. teach control means capable of controlling the signal processing means (col. 4, lines 43-64; col. 5, lines 55-67), when images are reconstructed immediately after the substantial measurement mode begins, so as to reconstruct images using data including data acquired in the pulse sequence performed previously (col. 7, lines 39-49 and lines 57-58). Kaufman et al. teach an apparatus capable of transforming three-dimensional data

Art Unit: 3737

of the time-series images to a two-dimensional projected image to be displayed on said display means (col. 1, lines 36-40; col. 4, line 62 – col. 5, line 3; col. 8, lines 11-13). Kaufman et al. teach that the mode switching means has an input means for mode switching (col. 4, lines 41-43), and the monitoring mode is switched to the substantial measurement mode by directly inputting a switching instruction to said mode switching means (col. 4, lines 43-45; col. 7, lines 17-23 and 47-49; col. 6, lines 39-43). Kaufman et al. teach that the gradient magnetic fields include a slice encode, a phase encode and a frequency encode for the two-dimensional or three-dimensional measurement (col. 4, lines 33-35; col. 6, lines 49-53; col. 8, lines 8-12; col. 6, lines 35-39). Since the physician or operator using the apparatus as taught by Kaufman et al. is capable of changing these parameters, the particular way in which they are executed is dependent on the desired diagnostic procedure of the physician or operator. Kaufman et al. teach that low resolution images, which are images taken during the monitoring mode, are first acquired near the center of K-space (col. 8, lines 57-59) and that higher resolution images, which are images associated with substantial measurement mode imaging, are acquired after a few pulse sequence duration (TR) periods. See col. 8, lines 59-60.

It would have been obvious to one of ordinary skill in the art at the time of the invention to understand that a signal value will be detected at or near the origin of the k-space and that since low resolution images are generated when acquisition is started near the center of the K-space, the signal value detected at the center of the k-space is indicative of being in a monitoring mode. Furthermore, it is known that as the TR periods increase, the K-space will be scanned further away from its center, and as

Kaufman et al. teach, higher resolution images will be generated indicating a switch from monitoring mode to substantial measurement mode. Examiner notes that the predetermined threshold value as taught by Kaufman et al. would be the number of TR periods.

5. Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kaufman et al. (6,690,961) in view of Geraats et al. (WO 02/04970).

Kaufman et al. do not explicitly teach the reference data as NMR signals acquired in the monitoring mode

Geraats et al. teach the reference data as NMR signals acquired in the monitoring mode (p.2, line 23 – p. 3, line 25).

It would have been obvious to one having ordinary skill in the art at the time of the invention to include reference data in the form of NMR signals acquired in the monitoring mode for determination of switching between monitoring mode and substantial measurement mode in the invention taught by Kaufman et al., in light of the teachings of Geraats et al. in order to add an additional control feature for the assurance of high quality MR vascular imaging (col. 1, line 47).

6. Claims 10-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaufman et al. (6,690,961) in view of Geraats et al. (WO 02/04970).

Kaufman et al. teach an apparatus capable of MR vascular imaging (col. 1, lines 43-56). As stated above, the physician or operator using the apparatus as taught by Kaufman et al. is capable of changing parameters, such as slice encode,

Page 6

therefore, the particular way in which a parameter is executed is dependent on the desired diagnostic procedure of the physician or operator.

Kaufman et al. do not explicitly teach an apparatus capable of blood imaging for observing a change of blood flow using a contrast agent, wherein a difference image between the blood images acquired before and after injection of the contrast agent is displayed on the displaying means.

It is well know in the art to use angiography for measuring and/ or assessing blood flow. Geraats et al. teach an apparatus capable of blood imaging for observing a change of blood flow using a contrast agent (p. 1, line 26 – p. 2, line 11), wherein a difference image between the blood images acquired before and after injection of the contrast agent is displayed on the displaying means (p. 4, line 32- p. 5, line 7).

It would have been obvious to one having ordinary skill in the art at the time of the invention to include blood imaging for observing a change of blood flow using a contrast agent, wherein a difference image between the blood images acquired before and after injection of the contrast agent is displayed on the displaying means in the Kaufman et al. invention, in light of the teachings of Geraats et al. in order to improve medical diagnosis provided from MR vascular imaging as taught by Kaufman et al (col. 1, lines 43-47).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Crystal I. Leach whose telephone number is 571-272-5211. The examiner can normally be reached on Monday through Friday, 8 am - 4:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/BRIAN CASLER/ Supervisory Patent Examiner, Art Unit 3737

/Crystal I Leach/ Examiner, Art Unit 3737 Application/Control Number: 10/517,102

Page 8

Art Unit: 3737